Skip to content

Taysha Gene Therapies, Inc. TSHA Payment Of Shelf Registration Costs

Other financials

Income statement

See full
Revenue--100%
Operating income-$43.5M-103%
Net income-$42.4M-97.0%
EPS (diluted)-$0.12-50.0%

Balance sheet

See full
Cash & equivalents$276.6M+137%
Total debt$68.6M+11.2%
Total equity$211.9M+285%
Total assets$300.4M+117%

Cash flow

See full
Operating cash flow-$40.9M-85.6%
CapEx$24.0K-93.7%
Free cash flow-$40.9M-82.6%

Valuation

See full
Market cap$1.99B+351%

Profitability

See full
Operating margin-1,774.4%+1,437pp
Net margin-1,738.4%+1,407pp
FCF margin-1,503.6%+621pp

Returns & leverage

See full
Return on equity-97.3%-27.3pp
Debt / equity0.3×-0.8×
Current ratio14×+8.7×

Where this comes from

Reported directly by Taysha Gene Therapies, Inc. in its filing.

Tagged under the XBRL concept tsha:PaymentOfShelfRegistrationCosts.

The official record: Taysha Gene Therapies, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Taysha Gene Therapies, Inc.'s payment of shelf registration costs?
Taysha Gene Therapies, Inc. (TSHA) reported payment of shelf registration costs of $47K in Q1 2025.